{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:45:33Z","timestamp":1788954333289,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_184816"],"award-info":[{"award-number":["310030_184816"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jaci.2022.06.008","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T13:32:32Z","timestamp":1659619952000},"page":"251-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Are blood cytokines reliable biomarkers of allergic disease diagnosis and treatment responses?"],"prefix":"10.1016","volume":"150","author":[{"given":"Susanne","family":"Radonjic-Hoesli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Pavlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Uwe","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.06.008_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jaci.2022.06.008_bib2","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","article-title":"Biomarkers for atopic dermatitis: a systematic review and meta-analysis","volume":"15","author":"Thijs","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1067\/mai.2002.126079","article-title":"Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis","volume":"110","author":"Fujisawa","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","article-title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis","volume":"113","author":"Hijnen","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/jdv.16698","article-title":"Serum thymus and activation-regulated chemokine levels before and after treatment for pruritic scabies","volume":"34","author":"Arakawa","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2022.06.008_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2010.02.015","article-title":"Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitis","volume":"63","author":"Kwakkel-van Erp","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2022.06.008_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2133.2003.05066.x","article-title":"High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid","volume":"148","author":"Kakinuma","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2022.06.008_bib10","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2014.07.031","article-title":"Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity","volume":"71","author":"Landheer","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2022.06.008_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2003.132","article-title":"Thymus and activation-regulated chemokine (TARC\/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides","volume":"48","author":"Kakinuma","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2022.06.008_bib13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2222.2006.02430.x","article-title":"Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis","volume":"36","author":"Song","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjd.18565","article-title":"Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials","volume":"183","author":"Katoh","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2022.06.008_bib15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1067\/mai.2002.127003","article-title":"High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome","volume":"110","author":"de Lavareille","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1399-3038.2007.00692.x","article-title":"Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis","volume":"19","author":"Nakazato","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2022.06.008_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1684\/ecn.2017.0390","article-title":"Increased serum IL-17A and Th2 cytokine levels in patients with severe uncontrolled asthma","volume":"28","author":"Hasegawa","year":"2017","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.jaci.2022.06.008_bib19","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1111\/all.14448","article-title":"Serum cytokine concentrations and asthma persistence to middle age","volume":"75","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13673","article-title":"Blood cytokine profiles - potential biomarkers for asthma persistence into adulthood?","volume":"33","author":"Fong","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/adc.83.2.158","article-title":"Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma","volume":"83","author":"Sahid El-Radhi","year":"2000","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaci.2022.06.008_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jim.2015.08.006","article-title":"Development of an ultra-sensitive single molecule counting assay for the detection of interleukin-13 as a marker for asthmatic severity","volume":"426","author":"Gaye","year":"2015","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jaci.2022.06.008_bib23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.201403-0505OC","article-title":"Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma","volume":"190","author":"Cheng","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.rmed.2016.11.020","article-title":"Association of interleukin-25 levels with development of aspirin induced respiratory diseases","volume":"123","author":"Lee","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12724","article-title":"Elevated levels of interleukin-33 are associated with allergic and eosinophilic asthma","volume":"89","author":"Gasiuniene","year":"2019","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000442413","article-title":"Universal Scientific Education and Research Network (USERN). Serum IL-33 is elevated in children with asthma and is associated with disease severity","volume":"168","author":"Bahrami Mahneh","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3109\/02770903.2014.921196","article-title":"IL-33 promotes airway remodeling and is a marker of asthma disease severity","volume":"51","author":"Guo","year":"2014","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2022.06.008_bib28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.anai.2018.05.005","article-title":"Minimally invasive biomarker studies in eosinophilic esophagitis: a systematic review","volume":"121","author":"Hines","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3390\/biom11060890","article-title":"Searching for noninvasive predictors of the diagnosis and monitoring of eosinophilic esophagitis-the importance of biomarkers of the inflammatory reaction involving eosinophils","volume":"11","author":"Sarbinowska","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaci.2022.06.008_bib30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jaci.2017.10.006","article-title":"Chronic rhinosinusitis: endotypes, biomarkers, and treatment response","volume":"140","author":"Gurrola","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fimmu.2019.00074","article-title":"Eotaxin-3 as a plasma biomarker for mucosal eosinophil infiltration in chronic rhinosinusitis","volume":"10","author":"Yamada","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108515","article-title":"Circulating BAFF as novel biomarker in distinguishing chronic rhinosinusitis with nasal polyps endotypes and predicting postoperative recurrence","volume":"104","author":"Wang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2022.06.008_bib34","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1177\/1945892420983787","article-title":"Evaluation of serum total immunoglobulin E, interleukin-17 and pentraxin-3 as biomarkers for chronic rhinosinusitis with nasal polyposis","volume":"35","author":"Hussien","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/cea.12463","article-title":"Immunological profiling in chronic rhinosinusitis with nasal polyps reveals distinct VEGF and GM-CSF signatures during symptomatic exacerbations","volume":"45","author":"Divekar","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1513\/AnnalsATS.201609-720OC","article-title":"Serum periostin as a biomarker for comorbid chronic rhinosinusitis in patients with asthma","volume":"14","author":"Asano","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaci.2022.06.008_bib37","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.06.008_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.aller.2019.04.011","article-title":"The utility of TNF-\u03b1, IL-6 and IL-10 in the diagnosis and\/or follow-up food allergy","volume":"48","author":"Kara","year":"2020","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2022.06.008_bib39","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apa.13550","article-title":"Changes in biomarkers during a six-month oral immunotherapy intervention for cow's milk allergy","volume":"105","author":"Salmivesi","year":"2016","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jaci.2022.06.008_bib40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jaci.2021.04.012","article-title":"Acute FPIES reactions are associated with an IL-17 inflammatory signature","volume":"148","author":"Berin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jdv.14541","article-title":"Different expression patterns of plasma Th1-, Th2-, Th17- and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria","volume":"32","author":"Chen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2022.06.008_bib42","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1365-2222.2011.03789.x","article-title":"Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients","volume":"41","author":"Kasperska-Zajac","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib43","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/ijd.14812","article-title":"IFN-\u03b3\/IL-6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy","volume":"59","author":"Grieco","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2022.06.008_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18187-z","article-title":"Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria","volume":"7","author":"Lin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2022.06.008_bib45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2340\/00015555-3149","article-title":"Serum miR-125a-5p and CCL17 upregulated in chronic spontaneous urticaria and correlated with treatment response","volume":"99","author":"Zhang","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2022.06.008_bib46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1399-3038.2009.00851.x","article-title":"Serum measurement of thymus and activation-regulated chemokine\/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis","volume":"20","author":"Fujisawa","year":"2009","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib47","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jaci.2004.05.066","article-title":"Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment","volume":"114","author":"Simon","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib48","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jaci.2017.03.023","article-title":"Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis","volume":"140","author":"Thijs","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2020.04.062","article-title":"Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers","volume":"147","author":"Bakker","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.anai.2014.04.013","article-title":"Differentiating asthma phenotypes in young adults through polyclonal cytokine profiles","volume":"113","author":"Zoratti","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.clim.2012.03.001","article-title":"Dynamic role of epithelium-derived cytokines in asthma","volume":"143","author":"Bartemes","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib52","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1136\/thx.49.12.1231","article-title":"Serum interleukin 5 concentrations in atopic and nonatopic patients with glucocorticoid-dependent chronic severe asthma","volume":"49","author":"Alexander","year":"1994","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2022.06.008_bib53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cyto.2011.05.011","article-title":"Increased interleukin-4 and decreased interferon-\u03b3 levels in serum of children with asthma","volume":"55","author":"Lama","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2022.06.008_bib54","first-page":"72","article-title":"Immunological parameters and gene polymorphisms (C-590T IL4, C-597A IL10) in severe bronchial asthma in children from the Krasnoyarsk region, West Siberia","volume":"5","author":"Smolnikova","year":"2013","journal-title":"Int J Circumpolar Health"},{"key":"10.1016\/j.jaci.2022.06.008_bib55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.rmed.2019.06.024","article-title":"Serum levels of IL-5, IL-6, IL-8, IL-13 and IL-17A in pre-defined groups of adult patients with moderate and severe bronchial asthma","volume":"154","author":"Dimitrova","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib56","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1097\/MD.0000000000003774","article-title":"A systemic inflammatory endotype of asthma with more severe disease identified by unbiased clustering of the serum cytokine profile","volume":"95","author":"Liang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaci.2022.06.008_bib57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.rmed.2017.03.002","article-title":"Serum cytokine profiles as predictors of asthma control in adults from the EGEA study","volume":"125","author":"Akiki","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib58","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/thoraxjnl-2018-212709","article-title":"Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study","volume":"74","author":"Busby","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2022.06.008_bib59","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014299","article-title":"Cytokine profiles in asthma families depend on age and phenotype","volume":"5","author":"Pukelsheim","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.06.008_bib61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/ppul.20747","article-title":"Exhaled nitric oxide for monitoring childhood asthma inflammation compared to sputum analysis, serum interleukins and pulmonary function","volume":"43","author":"Paro-Heitor","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaci.2022.06.008_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib63","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1365-2222.2008.02969.x","article-title":"IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells","volume":"38","author":"Chibana","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib64","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00413-2021","article-title":"Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma","volume":"58","author":"Kraft","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.06.008_bib65","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib66","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1164\/ajrccm.153.1.8542158","article-title":"Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients","volume":"153","author":"Kharitonov","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib68","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.06.008_bib69","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2022.06.008_bib70","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaci.2010.10.039","article-title":"A striking local esophageal cytokine expression profile in eosinophilic esophagitis","volume":"127","author":"Blanchard","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib71","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.cgh.2006.08.013","article-title":"Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis","volume":"4","author":"Konikoff","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2022.06.008_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2022.06.008_bib73","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/ajg.2015.57","article-title":"Utility of a noninvasive serum biomarker panel for diagnosis and monitoring of eosinophilic esophagitis: a prospective study","volume":"110","author":"Dellon","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2022.06.008_bib74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/apt.13672","article-title":"Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis","volume":"44","author":"Dellon","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaci.2022.06.008_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MCG.0000000000000621","article-title":"Longitudinal evaluation of noninvasive biomarkers for eosinophilic esophagitis","volume":"51","author":"Min","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jaci.2022.06.008_bib76","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2010.07.048","article-title":"Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis","volume":"139","author":"Straumann","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2022.06.008_bib77","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1111\/all.14874","article-title":"Noninvasive biomarkers identify eosinophilic esophagitis: a prospective longitudinal study in children","volume":"76","author":"Wechsler","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib78","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jaip.2021.03.029","article-title":"Immunological responses and biomarkers for allergen-specific immunotherapy against inhaled allergens","volume":"9","author":"Shamji","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.06.008_bib79","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaci.2010.12.1111","article-title":"A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response","volume":"127","author":"Varshney","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib80","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/cea.13256","article-title":"High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children","volume":"49","author":"Kulis","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib81","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaci.2010.12.1083","article-title":"Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization","volume":"127","author":"Kim","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib82","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/cea.12537","article-title":"Analysis of cytokine production by peanut-reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy","volume":"45","author":"Wisniewski","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.06.008_bib83","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jaci.2014.11.010","article-title":"Suppression of the immunologic response to peanut during immunotherapy is often transient","volume":"135","author":"Gorelik","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib84","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jaci.2016.08.017","article-title":"Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults","volume":"139","author":"Jones","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib85","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1159\/000515753","article-title":"Advanced biomarkers: therapeutic and diagnostic targets in urticaria","volume":"182","author":"Zhang","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.06.008_bib86","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jdermsci.2013.03.003","article-title":"Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, neopterin, and VEGF are not elevated in chronic spontaneous urticaria","volume":"70","author":"Metz","year":"2013","journal-title":"J Dermatol Sci"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922008387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922008387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:37:36Z","timestamp":1758793056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674922008387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0091674922008387"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.06.008","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are blood cytokines reliable biomarkers of allergic disease diagnosis and treatment responses?","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}